Last reviewed · How we verify

Dexmedetomidine with ropivacaine

Aristotle University Of Thessaloniki · FDA-approved active Small molecule Quality 5/100

Dexmedetomidine with ropivacaine is a Small molecule drug developed by Aristotle University Of Thessaloniki. It is currently FDA-approved. Also known as: DR.

Dexmedetomidine with ropivacaine, developed by Aristotle University of Thessaloniki, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique combination of dexmedetomidine and ropivacaine, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameDexmedetomidine with ropivacaine
Also known asDR
SponsorAristotle University Of Thessaloniki
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexmedetomidine with ropivacaine

What is Dexmedetomidine with ropivacaine?

Dexmedetomidine with ropivacaine is a Small molecule drug developed by Aristotle University Of Thessaloniki.

Who makes Dexmedetomidine with ropivacaine?

Dexmedetomidine with ropivacaine is developed and marketed by Aristotle University Of Thessaloniki (see full Aristotle University Of Thessaloniki pipeline at /company/aristotle-university-of-thessaloniki).

Is Dexmedetomidine with ropivacaine also known as anything else?

Dexmedetomidine with ropivacaine is also known as DR.

What development phase is Dexmedetomidine with ropivacaine in?

Dexmedetomidine with ropivacaine is FDA-approved (marketed).

Related